LUXDERM Specjalistyczny Gabinet Dermatologiczny Prof. dr hab. n. med. Dorota Krasowska — Clinical Trial Site

10 Registered trials

8 Currently recruiting

Organisation

LUXDERM Specjalistyczny Gabinet Dermatologiczny Prof. dr hab. n. med. Dorota Krasowska

Location

Lublin, Poland

Identifier

ORL-000009837

Address

Ul. Szafirowa 15/lok 45, 20-573, Poland

Departments

-
N/A
N/A. Private institution
NA

Clinical trials at this site (10)

Search interface

Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting

2024-519795-11-00 Atopic Dermatitis 4 2025-10-06
A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less… Recruiting

2025-522567-15-00 Plaque Psoriasis 5 2026-04-28
Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting

2025-522583-32-00 Cold-Induced Urticaria and Symptomatic Dermographism 5 2026-04-13
A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting

2025-522642-44-00 CHRONIC SPONTANEOUS URTICARIA 4 2026-03-18
A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting

2023-506296-97-00 Moderate to Severe Plaque Psoriasis 5 2025-10-28
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age with Moderate-to-Severe Atopic Eczema Recruiting

2023-509121-51-00 Moderate-to-Severe Atopic Dermatitis 5 2025-09-30
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A Multicenter trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects with Moderate-to-Severe Atopic … Ended

2024-514405-65-00 Atopic Dermatitis 4 2021-11-22